Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record.

Treatment of Histoplasmosis With Fluconazole in Patients With Acquired Immunodeficiency Syndrome

Open access
Wheat, Joe, MaWhinney, Samantha, Hafner, Richard, McKinsey, David, Chen, Dafeng, Korzun, Ann, Shakan, Kenneth J., Johnson, Phillip, Hamill, Richard, Bamberger, David, Pappas, Peter, Stansell, John, Koletar, Susan, Squires, Kathleen, Larsen, Robert A., Cheung, Tony, Hyslop, Newton, Lai, Kwan Kew, Schneider, Debra, Kauffman, Carol, Saag, Michael, Dismukes, William, Powderly, William·1997·The American Journal of Medicine

Abstract

PURPOSE: This study assesses the efficacy and safety of fluconazole therapy in patients with acquired immunodeficiency syndrome (AIDS) and mild to moderately severe manifestations of disseminated histoplasmosis. PATIENTS AND METHODS: This was a multicenter, open-label, nonrandomized prospective trial. All patients had AIDS and disseminated histoplasmosis. Patients were treated with 1,200 mg of fluconazole given by mouth once on the first day, then 600 mg once daily for 8 weeks, and those patients who improved clinically were then assigned fluconazole maintenance therapy 200 mg once daily for at least 1 year. Interim analysis revealed a high failure rate (10 of 20, 50%), causing revision of the protocol to increase the fluconazole dose to 1,600 mg given once on the first day, then 800 mg once daily, and the duration to 12 weeks for induction therapy and then 400 mg daily for 1 year for maintenance therapy. MEASUREMENTS AND MAIN RESULTS: Thirty-six of 49 patients (74%; 95% confidence interval [CI]: 59% to 85%) with mild to moderately severe clinical manifestations who entered into the revised study responded to 800 mg of fluconazole daily for 12 weeks as induction therapy. Of the seven patients who failed induction therapy because of progression of histoplasmosis, one died of the infection. Of 36 patients who entered into the maintenance phase of the study receiving 400 mg of fluconazole daily for 1 year, 11 (30.5%) relapsed, including one who died (2.8%). Two of the 49 patients (4.1%) were removed because of grade 4 adverse events, alkaline phosphatase elevation for one and aspartate aminotransferase elevation in the other. The relapse-free rate at 1 year was 53% (95% CI: 32% to 89%), prompting closure of the study. CONCLUSIONS: Fluconazole 800 mg daily is a safe and moderately effective induction therapy for mild or moderately severe disseminated histoplasmosis in patients with AIDS. On the basis of historic comparison, fluconazole 400 mg daily is less effective than itraconazole 200 to 400 mg daily or amphotericin B 50 mg given weekly as maintenance therapy to prevent relapse.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0002-9343(97)00151-4

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 158

Metadata

Authors
Wheat, J., MaWhinney, S., Hafner, R., McKinsey, D., Chen, D., Korzun, A., Shakan, K. J., Johnson, P., Hamill, R., Bamberger, D., Pappas, P., Stansell, J., Koletar, S., Squires, K., Larsen, R. A., Cheung, T., Hyslop, N., Lai, K. K., Schneider, D., Kauffman, C., Saag, M., Dismukes, W., & Powderly, W.
Venue
The American Journal of Medicine
Publisher
Elsevier BV
Published
1997-09
Volume
103
Issue
3
Pages
223-232
ISSN
0002-9343 (ISSN-L)
OpenAlex
W2029950196
Cited by
158
References
0
FWCI
5.27
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Histoplasmosis With Fluconazole in Patients With Acquired Immunodeficiency Syndrome. https://app.cochat.ai/papers/10.1016/s0002-9343(97)00151-4
The paper
Wheat, J., MaWhinney, S., Hafner, R., McKinsey, D., Chen, D., Korzun, A., Shakan, K. J., Johnson, P., Hamill, R., Bamberger, D., Pappas, P., Stansell, J., Koletar, S., Squires, K., Larsen, R. A., Cheung, T., Hyslop, N., Lai, K. K., Schneider, D., . . . Powderly, W. (1997). Treatment of Histoplasmosis With Fluconazole in Patients With Acquired Immunodeficiency Syndrome. The American Journal of Medicine. https://doi.org/10.1016/s0002-9343(97)00151-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.